NewsScientific Community

A Bitter Battle Over Insulin Gene

Science  22 Aug 1997:
Vol. 277, Issue 5329, pp. 1028-1030
DOI: 10.1126/science.277.5329.1028

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

When the University of California sued Eli Lilly and Company to uphold its patent rights on the insulin gene, little did it expect to come away empty-handed, with $12 million in legal bills and its researchers accused of "inequitable conduct." That's what happened 18 months ago, when a federal court ruled in Lilly's favor. Last month, an appeals court set aside the inequitable conduct ruling, but let stand the finding that Lilly did not infringe UC's patents.